Transcatheter Replacement for Bicuspid Aortic Valve Stenosis – Ready for Primetime?

A propensity-matched, observational study shows similar 1-year outcomes of TAVR for bicuspid and tricuspid disease, but stronger evidence is needed.

Although congenital bicuspid aortic valve (BAV) accounts for the majority of severe stenosis in younger patients, the condition was excluded from the randomized trials comparing transcatheter aortic valve replacement (TAVR) with surgery. In this observational study of the U.S. Transcatheter Valve Therapy Registry, investigators compared results of TAVR with a balloon-expandable prosthesis in low-surgical-risk patients with bicuspid disease and in those with tricuspid disease.

The proportion of patients with BAV was 9%, and the mean age and STS mortality risk score in the 3168 propensity-score–matched pairs were 69 years and 1.7%, respectively. Rates of death and stroke at 30 days and 1 year were similar in the bicuspid and tricuspid groups (…

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)